Compare Enveric Biosciences Inc (ENVB) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Stanley Black & Decker, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Stanley Black & Decker, Inc. trades at $90.64 (market cap $13.67B). The key difference: Stanley Black & Decker, Inc. is far larger — about 2569.5× Enveric Biosciences Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SWK | |
|---|---|---|
Market Cap | $5.32M | $13.67B |
Sector | Health | — |
52-Week High | $17.40 | $94.12 |
52-Week Low | $1.28 | $62.12 |
Enterprise Value | $408.82K | $19.84B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Stanley Black & Decker (SWK) trades at $87.37, up 0.97% on the day, with a neutral technical signal. The stock shows mixed fundamentals with a high P/E of 36.05 but attractive P/S of 0.88, while recent quarters have consistently beaten EPS estimates. Cash flow trends improved in 2025, and the company maintains a dividend with a recent $0.83 payout. News highlights strength in aerospace and automotive segments but notes Tools & Outdoor demand weakness.
Outlook is balanced: analyst consensus leans hold (51.35%) with a $82.75 price target below current levels. Opportunities include continued earnings beats and debt reduction, but risks involve high debt, segment volatility, and margin pressure. The stock presents a value case with momentum from execution, though macroeconomic headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
